AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B
Open Access
- 1 July 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 291 (1) , H239-H250
- https://doi.org/10.1152/ajpheart.01269.2005
Abstract
Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance.Keywords
This publication has 68 references indexed in Scilit:
- Ca2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cellsPublished by Elsevier ,2005
- Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinasePublished by Elsevier ,2005
- AMP-Activated Protein Kinase: A Key Stress Signaling Pathway in the HeartTrends in Cardiovascular Medicine, 2005
- AMP-activated protein kinase: balancing the scalesBiochimie, 2005
- Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro studyBiochemical Journal, 2004
- Combination of metformin and thiazolidindiones restore insulin signalling in insulin-resistant cultured myotubesLife Sciences, 2004
- New targets of AMP-activated protein kinaseBiochemical Society Transactions, 2003
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Development of Insulin Resistance in 3T3-L1 AdipocytesJournal of Biological Chemistry, 1997
- Diabetes and cardiovascular risk factors: the Framingham study.Circulation, 1979